谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Overall Survival and Efficacy Subgroup Analysis of Tunlametinib in Patients with Advanced NRAS-mutant Melanoma: A Multicenter, Open-Label, Single-Arm, Phase 2 Study.

Xiaoting Wei,Zhengyun Zou,Weizhen Zhang,Meiyu Fang, Hang‐Seok Chang,Zhiguo Luo,Jing Chen,Gang Huang,Peng Zhang,Ying Cheng,Jiwei Liu,Jiyan Liu,Junping Zhang,Di Wu,Yu Chen, Xiaobiao Ma,Hongqi Tian, Zhaojun Jia,Jun Guo,Lu Si

Journal of Clinical Oncology（2024）

引用 0|浏览0
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要